RecruitingNCT07663357
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
Sponsor
Beneficência Portuguesa de São Paulo
Enrollment
1,000 participants
Start Date
May 11, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with cardiotoxicity. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07663357
Related Trials
The STOP-MED CTRCD Trial
NCT0618343714 locations
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT066990568 locations
A Study of Blood Pressure Control During Cancer Treatment
NCT060235767 locations
Global Cardio Oncology Registry
NCT055988791 location
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
NCT075285861 location